Obtained special fund support from Beijing Municipal Commission of Science and Technology for the cultivation of pharmaceutical innovative varieties and platforms

In  March 2021, the "new generation of safe, high-yield and long-acting  leukemia bispecific antibody pre-clinical research" project declared by  our company was approved by the municipal science and technology  committee and received municipal financial support of 3.9 million yuan,  helping the company's scientific research team to develop rapidly in the  field of pharmaceutical research and development.